Prognostic Significance of Blood Brain-Derived Neurotrophic Factor (BDNF) in the Treatment of Various Functional and Organic Nervous System Diseases with Adaptol

The efficacy of using Adaptol in the complex treatment of patients with autonomic-vascular dystonia following closed craniocerebral trauma was studied. Patient status was evaluated before treatment started and after treatment ended, using clinical and neuropsychological scales, with simultaneous investigation of serum BDNF concentrations. On the background of Adaptol treatment, there was a significant ( p < 0.05) increase in the serum BDNF concentration, with showed a significant ( p < 0.05) correlation with decreases in the severity of anxiety and improvements in cognitive functions. The effects of the agent were dose-dependent. These results allow Adaptol to be recommended for the treatment of diseases requiring stimulation of neuroplasticity in the CNS.